Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).
This page lists clinical trials related to Retinal Disorders from the ClinicalTrials.gov database.
Trial Summary
- Total studies: 50
- Recruiting: 21
- Active, not recruiting: 10
- Completed: 8
- Other: 11
Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.
Recruiting Trials
NCT00001373 — Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Human Genome Research Institute (NHGRI) |
| Enrollment | 5000 |
| Study Type | OBSERVATIONAL |
| Conditions | Familial Mediterranean Fever (FMF); Autoinflammation; Periodic Fever; Fever; Genetic Diseases |
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.
The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) r…
NCT01109394 — Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 6035 |
| Study Type | OBSERVATIONAL |
| Conditions | Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer |
Background:
- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childh…
NCT02617966 — Rod and Cone Mediated Function in Retinal Disease
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Eye Institute (NEI) |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Retinal Degeneration; Retinitis Pigmentosa; Stargardt’s Disease |
Background:
Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.
Objectives:
To find out if how well a person sees in the dark can…
NCT04439708 — Biomarkers and Choroidal Neovascularization
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Enrollment | 250 |
| Study Type | OBSERVATIONAL |
| Conditions | Choroidal Neovascularization; Mineralocorticoid Excess |
| Interventions |
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
NCT03848663 — Visual Remapping to Aid Reading With Field Loss
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of Minnesota |
| Enrollment | 108 |
| Study Type | INTERVENTIONAL |
| Conditions | Age-related Macular Degeneration |
| Interventions | ; |
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
NCT05463289 — ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Johns Hopkins University |
| Enrollment | 500 |
| Study Type | INTERVENTIONAL |
| Conditions | Type 1 Diabetes; Type 2 Diabetes; Cystic Fibrosis-related Diabetes |
| Interventions |
The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.
NCT05726058 — Ocular Blood Flow Imaging for Glaucoma Assessment
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of Maryland, Baltimore |
| Enrollment | 150 |
| Study Type | INTERVENTIONAL |
| Conditions | Glaucoma |
| Interventions |
The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.
The main question it aims to answer are:
- Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?
- Can the investiga…
NCT06237127 — Effects of Goji vs. Fiber on Macular Degeneration
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of California, Davis |
| Enrollment | 60 |
| Study Type | INTERVENTIONAL |
| Conditions | Age-Related Macular Degeneration |
| Interventions | ; |
The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.
NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Janssen Research & Development, LLC |
| Enrollment | 274 |
| Study Type | INTERVENTIONAL |
| Conditions | Geographic Atrophy; Macular Degeneration |
| Interventions | ; |
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
NCT06701721 — A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Therini Bio Pty Ltd |
| Enrollment | 21 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Macular Edema; Diabetic Retinopathy |
| Interventions |
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Geographic Atrophy; Macular Degeneration |
| Interventions |
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of…
NCT06789445 — A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | BlueRock Therapeutics |
| Enrollment | 54 |
| Study Type | INTERVENTIONAL |
| Conditions | Primary Photoreceptor Disease; Retinitis Pigmentosa (RP); Usher Syndrome; Inherited Retinal Disease (IRD); Rod-Cone Dystrophy |
| Interventions | ; |
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 o…
NCT07680244 — (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Carl Zeiss Meditec-Dublin CoCe |
| Enrollment | 400 |
| Study Type | INTERVENTIONAL |
| Conditions | Epiretinal Membrane; Dry Age Related Macular Degeneration; Macular Abnormalities; Retina Disease; Vitreoretinal Abnormality |
| Interventions |
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
NCT07215234 — A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Sanofi |
| Enrollment | 104 |
| Study Type | INTERVENTIONAL |
| Conditions | Geographic Atrophy |
| Interventions | ; |
This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase.
T…
NCT07146516 — Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Helen Keller Eye Research Foundation |
| Enrollment | 500 |
| Study Type | INTERVENTIONAL |
| Conditions | Stickler Syndrome Type 1; Stickler Syndrome Type 2 |
| Interventions |
The goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults.
Researchers will compare the OSC/SS procedure in SS to the natural progression of SS to see to what extent the OSC/SS procedure works to prevent retinal detachment.
Participants will:
- Have the OSC/SS…
NCT07354477 — Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Qlaris Bio, Inc. |
| Enrollment | 14 |
| Study Type | INTERVENTIONAL |
| Conditions | Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG) |
| Interventions | ; |
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
NCT07587515 — Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Eyconis INC. |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Neovascular (Wet) Age-Related Macular Degeneration |
| Interventions |
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
NCT07419334 — Study of ALK-001 on the Progression of Stargardt Disease
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Alkeus Pharmaceuticals, Inc. |
| Enrollment | 230 |
| Study Type | INTERVENTIONAL |
| Conditions | Stargardt Disease |
| Interventions | ; |
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
NCT07592273 — Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
| Status | Recruiting |
| Phase | Phase 2 / Phase 3 |
| Sponsor | AbbVie |
| Enrollment | 576 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Retinopathy |
| Interventions | ; ; |
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (…
NCT07341763 — Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of Waterloo |
| Enrollment | 20 |
| Study Type | INTERVENTIONAL |
| Conditions | Retinitis Pigmentosa (RP); Rod Cone Dystrophy; Visually Impaired Persons; Peripheral Visual Field Defect of Both Eyes; Low Vision, Both Eyes |
| Interventions | ; |
This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the partic…
NCT04401982 — Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Maryland, Baltimore |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Ocular Hypertension; Suspect Glaucoma |
| Interventions | ; |
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and l…
Active, Not Recruiting
NCT00594672 — Age-Related Eye Disease Study (AREDS) Follow-Up
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | National Eye Institute (NEI) |
| Enrollment | 110 |
| Study Type | OBSERVATIONAL |
| Conditions | Age-Related Macular Degeneration; Cataract |
This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study.
Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination incl…
NCT01736293 — Natural History of Eye Diseases Related to ABCA4 Mutations
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | National Eye Institute (NEI) |
| Enrollment | 68 |
| Study Type | OBSERVATIONAL |
| Conditions | Retinal Degeneration; ABCA4-Related Retinopathies |
Background:
- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such as in Stargardt s disease), waste material from dead cells collects in the eye. The waste material may cause other cells in the eye to die. This can lead to the loss of vision. Researchers want to look at blood and skin samples from people with ABCA4 gene mutations to study rel…
NCT03655223 — Early Check: Expanded Screening in Newborns
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | RTI International |
| Enrollment | 30000 |
| Study Type | OBSERVATIONAL |
| Conditions | Spinal Muscular Atrophy; Fragile X Syndrome; Fragile X - Premutation; Duchenne Muscular Dystrophy; Hyperinsulinemic Hypoglycemia, Familial 1 |
| Interventions |
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health condi…
NCT03944239 — Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Sponsor | Qi Zhou |
| Enrollment | 25 |
| Study Type | INTERVENTIONAL |
| Conditions | Retinitis Pigmentosa |
| Interventions |
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP…
NCT05705258 — A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Bayer |
| Enrollment | 75 |
| Study Type | OBSERVATIONAL |
| Conditions | Retinopathy of Prematurity; Newborns; Infants |
| Interventions |
This is an observational study to collect data from Japanese babies with retinopathy of prematurity (ROP) who will be treated with Eylea. In observational studies, only observations are made without specified advice or interventions.
ROP is a condition that affects the eye and occurs only in babies who are born too early. Most cases of ROP are mild and get better without treatment, but more se…
NCT05957276 — Global Patient Registry of Inherited Retinal Diseases
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Janssen Research & Development, LLC |
| Enrollment | 888 |
| Study Type | OBSERVATIONAL |
| Conditions | Inherited Retinal Diseases |
| Interventions |
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Sponsor | Janssen Pharmaceutical K.K. |
| Enrollment | 4 |
| Study Type | INTERVENTIONAL |
| Conditions | Retinitis Pigmentosa |
| Interventions | ; |
The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
NCT06321302 — A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 190 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Retinopathy |
| Interventions | ; ; |
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Part…
NCT07341919 — Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
| Status | Active, not recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Rubens Camargo Siqueira |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Extensive Macular Atrophy With Pseudodrusen (EMAP); Retinitis Pigmentosa (RP) |
| Interventions |
his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP).
Participants will receive three subtenon injections of autologous platelet-rich plasma (1.5 mL per injection) administered at two-month interv…
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
| Status | Active, not recruiting |
| Phase | Phase 4 |
| Sponsor | Astellas Pharma Inc |
| Enrollment | 17 |
| Study Type | INTERVENTIONAL |
| Conditions | Geographic Atrophy; Age-Related Macular Degeneration |
| Interventions |
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovasc…
Not Yet Recruiting
NCT07690436 — Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | AstraZeneca |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Transthyretin Amyloid Cardiomyopathy |
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and prelim…
NCT07240649 — Emerging Indications for Hyperbaric Oxygen Treatment
| Status | Not yet recruiting |
| Phase | Phase 4 |
| Sponsor | Jay C. Buckey Jr. |
| Enrollment | 100 |
| Study Type | INTERVENTIONAL |
| Conditions | Post-COVID-19 Condition; Ulcerative Colitis; Crohn Disease; Calciphylaxis; Frostbite |
| Interventions | ; |
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The re…
NCT07681778 — Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
| Status | Not yet recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Opus Genetics, Inc |
| Enrollment | 10 |
| Study Type | INTERVENTIONAL |
| Conditions | Leber Congenital Amaurosis; Leber Congenital Amaurosis (LCA); LCA5 |
| Interventions |
This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a one-time injection (300 µL) into the retina (subretinal space) of the worse-seeing eye, using a method similar to app…
NCT07685886 — MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
| Status | Not yet recruiting |
| Phase | Phase 4 |
| Sponsor | University of Colorado, Denver |
| Enrollment | 110 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetes; Kidney Disease; Vascular Disease; Retinopathy |
| Interventions | ; |
Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may repre…
NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Proliferative Vitreoretinopathy; Proliferative Vitreo-Retinopathy; Rhegmatogenous Retinal Detachment |
| Interventions |
The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from an open globe injury, and compare the outcomes to those who do no receive intravitreal topotecan. The main objectives it aims to achieve are:
- to study the safety pro…
NCT07681167 — Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Sponsor | Singapore National Eye Centre |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Central Serous Chorioretinopathy (CSC) |
| Interventions | ; |
Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.
This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR …
NCT07290530 — 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Nacuity Pharmaceuticals, Inc. |
| Enrollment | 80 |
| Study Type | INTERVENTIONAL |
| Conditions | Retinitis Pigmentosa (RP); Usher Syndrome |
| Interventions | ; |
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:
Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI…
NCT07216924 — Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | University of Minnesota |
| Enrollment | 100 |
| Study Type | INTERVENTIONAL |
| Conditions | Macular Degeneration; Central Visual Impairment |
| Interventions | ; ; |
Reading performance in patients with Central Vision Loss will be measured with and without missing text being remapped to different parts of the visual field in a variety of different reading tasks.
Enrolling by Invitation
NCT07682025 — Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.
| Status | Enrolling by invitation |
| Phase | N/A |
| Sponsor | University College, London |
| Enrollment | 100 |
| Study Type | OBSERVATIONAL |
| Conditions | Proliferative Vitreoretinopathy |
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).
Study aims to help tailor patients’ treatments and improve outcomes by:
[i] studying imaging biomarkers of PVR, and [ii] develop AI models for PVR detection.
Inclusion:
- Patients with ‘complicated’ retinal detach…
Completed Trials
NCT00055029 — Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis
| Status | Completed |
| Phase | N/A |
| Sponsor | National Eye Institute (NEI) |
| Enrollment | 351 |
| Study Type | OBSERVATIONAL |
| Conditions | Retinoschisis |
This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the back of the eye). A better understanding of why and how XLRS develops might lead to improved treatme…
NCT01352975 — Study of Dark Adaptation in Age-Related Macular Degeneration
| Status | Completed |
| Phase | N/A |
| Sponsor | National Eye Institute (NEI) |
| Enrollment | 217 |
| Study Type | OBSERVATIONAL |
| Conditions | Age-Related Macular Degeneration |
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more serious form and can result in…
NCT02210130 — The Microvascular Brain Retina And Kidney Study
| Status | Completed |
| Phase | N/A |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Enrollment | 163 |
| Study Type | OBSERVATIONAL |
| Conditions | Cerebral Small Vessels Disease |
Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. CSVD is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. While HIV patients share the same cardiovascular risk factors …
NCT03584165 — Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | NightstaRx Ltd, a Biogen Company |
| Enrollment | 277 |
| Study Type | INTERVENTIONAL |
| Conditions | Choroideremia; X-Linked Retinitis Pigmentosa |
| Interventions | ; |
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants wi…
NCT04355689 — Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
| Status | Completed |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Nacuity Pharmaceuticals, Inc. |
| Enrollment | 49 |
| Study Type | INTERVENTIONAL |
| Conditions | Usher Syndromes |
| Interventions | ; |
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
NCT04505566 — INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Stephen J. Kim, MD |
| Enrollment | 164 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Retinopathy |
| Interventions | ; ; |
The central hypothesis is that inflammation mediators are biomarkers of both systemic diabetes and Diabetic Retinopathy (DR) progression in the aqueous and that sustained topical ketorolac application reduces/suppresses those inflammatory mediators thereby reducing the progression of Diabetic Retinopathy.
NCT06164587 — Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
| Status | Completed |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Michelle Abou-Jaoude |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Geographic Atrophy; Age-Related Macular Degeneration |
| Interventions |
This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30.
Participants …
NCT07690800 — Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage
| Status | Completed |
| Phase | Phase 4 |
| Sponsor | Benha University |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Vitreous Hemorrhage; Intravitreal Injections; Ranibizumab |
| Interventions |
This prospective interventional cohort study evaluates the outcomes of intravitreal ranibizumab injection in patients with diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy. The study aims to assess the effectiveness of ranibizumab in improving visual acuity, promoting vitreous hemorrhage clearance, reducing the need for pars plana vitrectomy, and evaluating treatment…
Other (Suspended)
NCT01878045 — Mechanisms of Diabetic Kidney Disease in American Indians
| Status | Suspended |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 141 |
| Study Type | OBSERVATIONAL |
| Conditions | Nervous System; Diabetic Kidney Disease; Diabetes Mellitus, Type 2 |
Background:
- An ongoing study is looking at American Indians who have kidney problems caused by type 2 diabetes. Kidney disease due to type 2 diabetes is a major problem in American Indians. We previously found that early treatment of kidney disease with losartan was probably beneficial for reducing progression of the disease. Researchers now want to see if these benefits continue to be seen…
Other (Terminated)
NCT04699864 — Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM
| Status | Terminated |
| Phase | N/A |
| Sponsor | Centre hospitalier de l’Université de Montréal (CHUM) |
| Enrollment | 24 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Retinopathy; Diabetic Macular Edema; Diabetic Maculopathy |
| Interventions | ; ; |
This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.